The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Abstract

Background Atherosclerosis is a chronic lipid-driven inflammatory disease with infiltration of low-density lipoprotein and is considered as the pivotal step in plaque formation. The aim of the review is to get into the fine details of pathophysiologic mechanisms responsible for atherosclerosis with atherosclerotic lesion classification. It also provides a summary of current biomarkers other than the traditional risk factors so that new treatment modalities can emerge and reduce the morbidity and mortality associated with atherosclerosis. Main body In the classification of atherosclerosis made by American Heart Association (AHA), AHA Type I lesion is the earliest vascular change described microscopically. AHA Type II lesion is primarily composed of abundant macrophages. AHA Type III lesion is the earliest of progressive lesions, while AHA Type IV lesion consists of an acellular necrotic core. Various biomarkers are implicated in different stages of the pathophysiological mechanism of plaque formation and evolution. C Reactive Protein plays a direct role in promoting the inflammatory component of atherosclerosis. Fibrinogen was demonstrated to be elevated among patients with acute thrombosis. Higher leukocyte count is associated with a greater cardiovascular risk. Cytokines have been implicated in atheroma formation and complications. High rates of protease activated receptor expression are also induced by interleukin-6 secretion in atherosclerotic lesions and areas of vascular tissue injury. Cluster of differentiation 40 receptor and its ligand have been also detected in atherosclerotic plaques. Osteopontin, acidic phosphoprotein, and osteoprotegerin have emerged as novel markers of atherosclerotic plaque composition. There are also overproductions of matrix metalloproteinases in the rupture-prone regions and promote lipid-necrotic core formation in the atherosclerotic plaque. Myeloperoxidase has been proposed as a marker of plaque instability. Oxidized low-density lipoprotein receptor 1 provides a route of entry for oxidized low-density lipoprotein into the endothelium. A human atherosclerotic lesion also expresses lipoprotein-associated phospholipase A2. Short conclusion Atherosclerotic plaques are the battlefield between an unbalanced immune response and lipid accumulation in the intima of arteries. Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response and will also be used for medical purposes.

Uncovering the Power of GPR18 Signalling: How RvD2 and Other Ligands Could Have the Potential to Modulate and Resolve Inflammation in Various Health Disorders

“…Atherosclerotic lesions are a common chronic inflammation condition characterised by the accumulation of lipids, cholesterol, and fibrous elements in the large arteries, causing an inhibition of blood flow [ 52 ]. Resolution signalling in cardiovascular diseases is a clue to treatment success.…”

The Probable Role of Chlamydia pneumoniae Infection in Acute Stroke

“…The type IV lesions (atheroma) can evolve to any of the further stages. The progression does not need to be in a sequential manner [54]. The fate of plaque is determined by the following mechanisms: lipid retention rate, macrophage phenotype, inflammation, apoptosis and necrosis, smooth muscle cell proliferation, arterial remodeling, and stability of fibrous cap.…”

Anti-oxidant Response of Lipidom Modulates Lipid Metabolism inCaenorhabditis elegansand in OxLDL-Induced Human Macrophages by Tuning Inflammatory Mediators

“…TNF-α, is a major proinflammatory cytokine which activates NFκB which aids in the release of inflammatory cytokines. Inflammatory mediators namely IL-1β, MCP-1 furthers the atherosclerotic plaque formation by migration, infiltration, proliferation, and differentiation of immune cells like monocytes and macrophages which leads to the development of chronic inflammation [6]. Lipidom (10,30, and 100 µg/ml) treatment significantly (p <0.001) decreased the TNF-α induced NFκB activity and also inhibited the IL-1β, MCP-1 release from the OxLDL (25 µg/ml) induced THP1 macrophages (Figure 4A-4C).…”